Senator Jennifer McClellan Favola (referred to as Senator Favola in transcript) presented SB 745, a section 1 bill directing the Board of Pharmacy to convene stakeholders to examine coverage of therapeutic interchange drugs across payer types—federal (branded law plans referenced as "Bridal" in the transcript), Medicare, Medicaid and private insurers—and to report back with recommendations by Nov. 15, 2025.

Favola said therapeutic interchange drugs can deliver the same clinical benefit as brand-name drugs but at lower cost, and the work group could produce recommendations to improve access and reduce costs for patients. There was no opposition recorded. The subcommittee moved and seconded to report the bill; Senators Boisco, Pillion, Bagby (aye by proxy), Head, Pokarski and Hashmi voted in favor and the motion passed unanimously in subcommittee.

The subcommittee recorded the bill as recommended to the full committee for further consideration and tasked the Board of Pharmacy to convene stakeholders and deliver a report in the fall of 2025.